United Therapeutics Management

Management criteria checks 3/4

United Therapeutics' CEO is Martine Rothblatt, appointed in Jan 1996, has a tenure of 28.25 years. total yearly compensation is $5.32M, comprised of 26.3% salary and 73.7% bonuses, including company stock and options. directly owns 1.37% of the company’s shares, worth €140.89M. The average tenure of the management team and the board of directors is 15 years and 21.5 years respectively.

Key information

Martine Rothblatt

Chief executive officer

US$5.3m

Total compensation

CEO salary percentage	26.3%
CEO tenure	28.3yrs
CEO ownership	1.4%
Management average tenure	15yrs
Board average tenure	21.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Martine Rothblatt's remuneration changed compared to United Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	US$985m
Sep 30 2023	n/a	n/a	US$900m
Jun 30 2023	n/a	n/a	US$872m
Mar 31 2023	n/a	n/a	US$728m
Dec 31 2022	US$5m	US$1m	US$727m
Sep 30 2022	n/a	n/a	US$707m
Jun 30 2022	n/a	n/a	US$631m
Mar 31 2022	n/a	n/a	US$687m
Dec 31 2021	US$4m	US$1m	US$476m
Sep 30 2021	n/a	n/a	US$462m
Jun 30 2021	n/a	n/a	US$471m
Mar 31 2021	n/a	n/a	US$405m
Dec 31 2020	US$5m	US$1m	US$515m
Sep 30 2020	n/a	n/a	US$469m
Jun 30 2020	n/a	n/a	US$430m
Mar 31 2020	n/a	n/a	US$528m
Dec 31 2019	US$46m	US$1m	-US$104m
Sep 30 2019	n/a	n/a	-US$92m
Jun 30 2019	n/a	n/a	-US$118m
Mar 31 2019	n/a	n/a	-US$150m
Dec 31 2018	US$16m	US$1m	US$589m
Sep 30 2018	n/a	n/a	US$543m
Jun 30 2018	n/a	n/a	US$713m
Mar 31 2018	n/a	n/a	US$484m
Dec 31 2017	US$37m	US$1m	US$418m

Compensation vs Market: Martine's total compensation ($USD5.32M) is about average for companies of similar size in the German market ($USD5.66M).

Compensation vs Earnings: Martine's compensation has increased by more than 20% in the past year.

CEO

Martine Rothblatt (68 yo)

28.3yrs

Tenure

US$5,322,204

Compensation

Dr. Martine A. Rothblatt, Ph D., J.D., M.B.A., founded United Therapeutics Corporation in 1996 and has been its Chief Executive Officer since June 26, 2016 and as its Chairman since 1996. Dr. Rothblatt ser...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Martine Rothblatt	Founder	28.3yrs	US$5.32m	1.37% $ 140.9m
Michael Benkowitz	President & COO	7.8yrs	US$2.83m	0.0052% $ 539.0k
James Edgemond	CFO & Treasurer	11.3yrs	US$2.01m	0.0031% $ 321.0k
Paul Mahon	Executive VP	28.3yrs	US$2.31m	0.078% $ 8.0m
Dewey Steadman	Head of Investor Relations	no data	no data	no data
Holly Hobson	Associate Vice President of Human Resources	no data	no data	no data
Kevin Gray	Senior Vice President of Strategic Operations & Logistics	no data	no data	no data
Patrick Poisson	Executive VP of Technical Operations	15yrs	no data	no data
Leigh Peterson	Executive Vice President of Product Development & Xenotransplantation	no data	no data	no data
Gil Golden	Senior VP & Chief Medical Officer	no data	no data	no data

15.0yrs

Average Tenure

55yo

Average Age

Experienced Management: UTH's management team is seasoned and experienced (15 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Martine Rothblatt	Founder	28.3yrs	US$5.32m	1.37% $ 140.9m
Samuel Thier	Member of the Scientific Advisory Board	no data	no data	no data
Raymond Kurzweil	Independent Director	22.3yrs	US$485.37k	0.024% $ 2.4m
Louis Sullivan	Independent Director & Member of the Scientific Advisory Board	21.6yrs	US$515.37k	0.028% $ 2.9m
Raymond Dwek	Independent Director & Member of the Scientific Advisory Board	22.3yrs	US$495.35k	0.0037% $ 382.7k
Christopher Patusky	Independent Vice Chairman & Lead Independent Director	21.5yrs	US$562.98k	0.0024% $ 241.7k
Christopher Causey	Independent Director	20.8yrs	US$520.35k	0.0089% $ 914.5k
Robert Bourge	Member of the Scientific Advisory Board	no data	no data	no data
Thomas Thompson	Independent Director	14.3yrs	US$500.37k	0.048% $ 4.9m
Magdi Yacoub	Member of the Scientific Advisory Board	no data	no data	no data
Richard Giltner	Independent Director	15yrs	US$520.35k	0.033% $ 3.4m
Katherine Klein	Independent Director	9.4yrs	US$485.37k	0.0077% $ 796.2k

21.5yrs

Average Tenure

75yo

Average Age

Experienced Board: UTH's board of directors are seasoned and experienced ( 21.5 years average tenure).

United Therapeutics Management

Management criteria checks 3/4

Key information

Recent management updates

Insufficient new directors

Insider recently sold €73k worth of stock

Insider recently sold €270k worth of stock

Insufficient new directors

Insider recently sold €78k worth of stock

Insider recently sold €269k worth of stock

Recent updates

United Therapeutics Corporation to Report Q1, 2024 Results on May 01, 2024

United Therapeutics Corporation (NasdaqGS:UTHR) announces an Equity Buyback for $1,000 million worth of its shares.

New minor risk - Insider selling

Full year 2023 earnings released: EPS: US$21.04 (vs US$15.99 in FY 2022)

United Therapeutics Corporation to Report Q4, 2023 Results on Feb 21, 2024

Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims

United Therapeutics Corporation Announces U.S. Court of Appeals for the Federal Circuit Issues A Decision Regarding Company's U.S. Patent No. 10,716,793

United Therapeutics Corporation (NasdaqGS:UTHR) completed the acquisition of Miromatrix Medical Inc. (NasdaqCM:MIRO) from Gagnon Securities, LLC and others

Insufficient new directors

Third quarter 2023 earnings released: EPS: US$5.71 (vs US$5.26 in 3Q 2022)

United Therapeutics Corporation (NasdaqGS:UTHR) entered into definitive agreement to acquire Miromatrix Medical Inc. (NasdaqCM:MIRO) from shareholders for $89.1 million.

United Therapeutics Corporation to Report Q3, 2023 Results on Nov 01, 2023

Second quarter 2023 earnings released: EPS: US$5.53 (vs US$2.56 in 2Q 2022)

United Therapeutics Corporation to Report Q2, 2023 Results on Aug 02, 2023

United Therapeutics Corporation to Report Q2, 2023 Results on Aug 02, 2023

Insider recently sold €73k worth of stock

First quarter 2023 earnings released: EPS: US$5.20 (vs US$5.31 in 1Q 2022)

Full year 2022 earnings released: EPS: US$15.99 (vs US$10.60 in FY 2021)

United Therapeutics Corporation to Report Q4, 2022 Results on Feb 22, 2023

Insider recently sold €270k worth of stock

Insufficient new directors

Insider recently sold €78k worth of stock

Third quarter 2022 earnings released: EPS: US$5.26 (vs US$3.62 in 3Q 2021)

United Therapeutics Announces Top Line Data from the EXPEDITE Study of Remodulin Induction Prior to Orenitram Therapy

United Therapeutics Corporation to Report Q3, 2022 Results on Nov 02, 2022

United Therapeutics Announces First Patient Enrolled in Phase 3 Teton 2 Study of Tyvaso in Patients with Idiopathic Pulmonary Fibrosis

Insider recently sold €269k worth of stock

Second quarter 2022 earnings released: EPS: US$2.56 (vs US$3.85 in 2Q 2021)

United Therapeutics Corporation to Report Q2, 2022 Results on Aug 03, 2022

United Therapeutics Corporation(NasdaqGS:UTHR) dropped from Russell 1000 Value-Defensive Index

Investor sentiment improved over the past week

United Therapeutics Corporation Announces FDA Approval of Tyvaso DPI

First quarter 2022 earnings released: EPS: US$5.31 (vs US$0.64 in 1Q 2021)

United Therapeutics Corporation, Annual General Meeting, Jun 27, 2022

Insufficient new directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

United Therapeutics Corporation to Report Q4, 2021 Results on Feb 24, 2022

United Therapeutics Corporation Announces Historic Achievements in Its Xenotransplantation Programs

United Therapeutics Corporation Receives Complete Response from the U.S. Food and Drug Administration

Key Executive recently sold €397k worth of stock

Third quarter 2021 earnings released: EPS US$3.62 (vs US$3.86 in 3Q 2020)

United Therapeutics Corporation to Present Tyvaso Dpi™ Breeze Clinical Data At the European Respiratory Society International Congress 2021

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS US$3.85 (vs US$2.43 in 2Q 2020)

United Therapeutics Announces FDA Acceptance of Tyvaso DPI™ New Drug Application For Priority Review

United Therapeutics Announces First Patient Enrolled in Phase 3 TETON Study Of Tyvaso In Patients With Idiopathic Pulmonary Fibrosis

First quarter 2021 earnings released: EPS US$0.64 (vs US$3.14 in 1Q 2020)

United Therapeutics Corporation Announces Impairment Charge for the Three Months Ended March 31, 2021

Investor sentiment improved over the past week

United Therapeutics Corporation Decides to Discontinue the Development of Trevyent® (Treprostinil)

Full year 2020 earnings released: EPS US$11.65 (vs US$2.39 loss in FY 2019)

Revenue beats expectations

United Therapeutics Corporation to Report Q4, 2020 Results on Feb 24, 2021

United Therapeutics Corporation Announces Commercial Launch Of The Remunity® Pump For Remodulin®

United Therapeutics Corporation Announces BREEZE Study of Investigational Tyvaso DPI Meets Primary Objective

United Therapeutics Corporation Announces New England Journal of Medicine Publication of the INCREASE Study Evaluating Tyvaso® in Pulmonary Hypertension Associated with Interstitial Lung Disease

New 90-day high: €124

New 90-day high: €121

New 90-day high: €120

Third-quarter earnings released: Revenue beats expectations

New 90-day high: €103

United Therapeutics to Present New Tyvaso® Clinical and Treprostinil Real-World Data At Chest Annual Meeting 2020

New 90-day low - €87.00

New 90-day low - €90.00

United Therapeutics Corporation to Report Q2, 2020 Results on Jul 29, 2020

New 90-day low - €97.50

CEO Compensation Analysis

CEO

Tenure